Home › Funds › DRIEHAUS CAPITAL MANAGEMENT LLC › CRNX
DRIEHAUS CAPITAL MANAGEMENT LLC position in CRNX
CRINETICS PHARMACEUTICALS IN
DRIEHAUS CAPITAL MANAGEMENT LLC reported holding 6,463,551 shares of CRNX (CRINETICS PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$241.9M, representing 1.40% of its reported portfolio and ranking #7 among its reported holdings. DRIEHAUS CAPITAL MANAGEMENT LLC has disclosed CRNX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How DRIEHAUS CAPITAL MANAGEMENT LLC's CRNX position evolved
DRIEHAUS CAPITAL MANAGEMENT LLC first disclosed a stake in CRNX in Q3 2023 at 5,132,287 shares (US$152.6M). The position peaked in Q4 2024 at 6,141,014 shares, worth US$314.0M. Across 12 filings, DRIEHAUS CAPITAL MANAGEMENT LLC increased the stake 7 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 6,463,551 shares valued at US$241.9M — an increase of 67,629 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 5.13M | $152.63M | New |
| Q4 2023 | 5.04M | $179.32M | Reduce |
| Q1 2024 | 5.23M | $244.64M | Add |
| Q2 2024 | 6.11M | $273.76M | Add |
| Q3 2024 | 5.89M | $300.74M | Reduce |
| Q4 2024 | 6.14M | $313.99M | Add |
| Q1 2025 | 6.24M | $209.29M | Add |
| Q2 2025 | 6.40M | $184.06M | Add |
| Q3 2025 | 6.48M | $269.96M | Add |
| Q4 2025 | 6.39M | $297.35M | Reduce |
| Q1 2026 | 6.40M | $232.30M | Hold |
| Q2 2026 | 6.46M | $241.87M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CRNX and 13F data
CRNX (CRINETICS PHARMACEUTICALS IN) is a company whose sector is not yet classified in our data. 37 other funds we track also report a position in CRNX — the largest reported positions include Farallon Capital Management (US$336.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$336.4M), Bellevue Group AG (US$98.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CRNX
- Farallon Capital Management 8.99M sh · $336.37M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 8.99M sh · $336.37M · Q2 2026
- Bellevue Group AG 2.62M sh · $98.04M · Q2 2026
- BAKER BROS. ADVISORS LP 2.35M sh · $87.99M · Q2 2026
- Siren, L.L.C. 1.42M sh · $53.17M · Q2 2026
- First Light Asset Management, LLC 1.36M sh · $50.92M · Q2 2026
- Novo Holdings A/S 1.32M sh · $49.39M · Q2 2026
- ADAR1 Capital Management, LLC 1.22M sh · $45.73M · Q2 2026
- MONTANOVA CAPITAL, LLC 1.19M sh · $44.39M · Q2 2026
- ORBIMED ADVISORS LLC 999.00K sh · $37.38M · Q2 2026
More on DRIEHAUS CAPITAL MANAGEMENT LLC
FAQ
How long has DRIEHAUS CAPITAL MANAGEMENT LLC held CRNX?
DRIEHAUS CAPITAL MANAGEMENT LLC has disclosed CRNX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is DRIEHAUS CAPITAL MANAGEMENT LLC's current position in CRNX?
As of Q2 2026, DRIEHAUS CAPITAL MANAGEMENT LLC holds 6.46M shares of CRNX (CRINETICS PHARMACEUTICALS IN), valued at $241.87M, representing 1.40% of its reported portfolio and ranking #7.
Has DRIEHAUS CAPITAL MANAGEMENT LLC been buying or selling CRNX?
In the latest 13F filing (Q2 2026), DRIEHAUS CAPITAL MANAGEMENT LLC increased its position in CRNX. The position peaked in Q4 2024 at 6.14M shares.
Which other funds hold CRNX?
Other major institutional holders of CRNX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., Bellevue Group AG, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.